JP2025011142A5 - - Google Patents

Info

Publication number
JP2025011142A5
JP2025011142A5 JP2024168470A JP2024168470A JP2025011142A5 JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5 JP 2024168470 A JP2024168470 A JP 2024168470A JP 2024168470 A JP2024168470 A JP 2024168470A JP 2025011142 A5 JP2025011142 A5 JP 2025011142A5
Authority
JP
Japan
Prior art keywords
application
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024168470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025011142A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/064032 external-priority patent/WO2020113224A2/en
Application filed filed Critical
Publication of JP2025011142A publication Critical patent/JP2025011142A/ja
Publication of JP2025011142A5 publication Critical patent/JP2025011142A5/ja
Pending legal-status Critical Current

Links

JP2024168470A 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法 Pending JP2025011142A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862773885P 2018-11-30 2018-11-30
US62/773,885 2018-11-30
US201962826462P 2019-03-29 2019-03-29
US62/826,462 2019-03-29
PCT/US2019/064032 WO2020113224A2 (en) 2018-11-30 2019-12-02 Chimeric antigen receptor factories and methods of use thereof
JP2021530875A JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021530875A Division JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2025011142A JP2025011142A (ja) 2025-01-23
JP2025011142A5 true JP2025011142A5 (enExample) 2025-10-15

Family

ID=70853578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法
JP2024168470A Pending JP2025011142A (ja) 2018-11-30 2024-09-27 キメラ抗原受容体ファクトリおよびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021530875A Active JP7649239B2 (ja) 2018-11-30 2019-12-02 キメラ抗原受容体ファクトリおよびその使用方法

Country Status (7)

Country Link
US (1) US20220047634A1 (enExample)
EP (1) EP3887509A4 (enExample)
JP (2) JP7649239B2 (enExample)
KR (1) KR20210135475A (enExample)
AU (1) AU2019387566A1 (enExample)
CA (1) CA3119644A1 (enExample)
WO (1) WO2020113224A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120795163A (zh) * 2016-10-14 2025-10-17 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
CN109401969B (zh) * 2018-12-13 2024-02-02 珠海西格膜生物技术有限公司 一种细胞工厂的管道连接系统及其使用方法
AU2020290971A1 (en) * 2019-06-14 2021-12-23 Dana-Farber Cancer Institute, Inc. Antibodies against PD-1 and methods of use thereof
CA3141927A1 (en) * 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
US20230399412A1 (en) * 2020-10-12 2023-12-14 Nanjing IASO Biotechnology Co., Ltd. Antibody and chimeric antigen receptor (car) binding to cd70, and application thereof
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN114565761B (zh) * 2022-02-25 2023-01-17 无锡市第二人民医院 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法
CN119584995A (zh) * 2022-06-09 2025-03-07 泰利斯制药(创新)有限公司 组合疗法
US12257304B2 (en) 2023-03-03 2025-03-25 Arsenal Biosciences, Inc. Systems targeting PSMA and CA9

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
CA2828753C (en) * 2011-03-16 2022-07-26 arGEN-X BV Antibodies to cd70
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US10870705B2 (en) * 2014-12-19 2020-12-22 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors specific for carbonic acid anhydrase IX
WO2016149578A1 (en) * 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
US20190031759A1 (en) * 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
MX2018005315A (es) 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc Composiciones y metodos para el tratamiento del cancer.
ES2900233T3 (es) 2017-02-14 2022-03-16 Kite Pharma Inc Moléculas que se unen a CD70 y métodos de uso de las mismas
EP3585817A4 (en) 2017-02-22 2020-12-02 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

Similar Documents

Publication Publication Date Title
JP2025027013A5 (enExample)
JP2025011142A5 (enExample)
JP2024116190A5 (enExample)
JP2023115329A5 (enExample)
JPWO2021188969A5 (enExample)
JP2024036694A5 (enExample)
JP2024032941A5 (enExample)
JP2022184985A5 (enExample)
JP2024114921A5 (enExample)
JP2023145572A5 (enExample)
JP2025069142A5 (enExample)
JP2022024034A5 (enExample)
JPWO2021237223A5 (enExample)
JP2025094038A5 (enExample)
JP2025090801A5 (enExample)
JP2025098156A5 (enExample)
JP2024149687A5 (enExample)
JP2024099585A5 (enExample)
JP2023093656A5 (enExample)
JPWO2021022008A5 (enExample)
JP2025003964A5 (enExample)
JP2024073452A5 (enExample)
JP2023085264A5 (enExample)
JP2023078173A5 (enExample)
JPWO2019183186A5 (enExample)